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disease severity (mildly ill, moderately ill, and severely ill). Treatment 
parameters are estimated using published information for once-daily risperidone 
standard oral therapy (RIS-SOT) and once-monthly risperidone long-acting 
injection (RIS-LAI) with LFA therapy characteristics derived from observed study 
trends. One-year and five-year results are expressed as discounted direct 
medical costs and mean number of relapses per patient (inpatient, outpatient, 
total) and are estimated for LFA therapies given at three, six, and nine month 
intervals. RESULTS: The one-year results show that LFA therapy every 3 months 
(LFA-3) ($6,088) is less costly than either RIS-SOT ($10,721) or RIS-LAI ($9,450) 
with similar trends in the 5-year results. Moreover, the model predicts that LFA-3 
versus RIS-SOT versus RIS LAI therapy will reduce costly inpatient relapses (0.16 
vs. 0.51 vs. 0.41). Extending the interval to six (LFA-6) and nine (LFA-9) months 
resulted in further reductions in relapse and costs. Limitations include the fact 
that LFA therapeutic options are hypothetical and do not yet exist and limited 
applicability to compare one antipsychotic agent versus another as only 
risperidone therapy is evaluated. CONCLUSIONS: These study results have 
quantified the potential health state improvements and potential direct medical 
cost savings achievable with the development and use of LFA medication 
delivery technologies.  
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OBJECTIVES: To examine the circumstances of the recognition of the autism, the 
problems in connection with the condition of the child as well as the 
opportunities, deficiencies of the support. METHODS: During the research as the 
first step the Autistic Association and its member organizations were selected. 
As the second step the families were reached through them. A total of 358 postal 
examinational questionnaires were sent; the interviewers visited 312 families. 
During my analysis the data of the samples between year 0-18 were used (276 
people). The process of the data was completed by SPSS program. RESULTS: The 
first symptoms of autism are perceived foremost by the parents that is followed 
by an at least 2 years period till the diagnosis. Only 30% of the children speak 
well, only 59% of the parents always understand them. The 38% of children have 
slight or severe insomnia. A total of 84% of the children have frequent or 
permanent behavioural disorders. Due to the child’s autism the families are 
isolated; 40% of the parents have been unemployed since the birth of their child. 
The assistance or communication between the concerned families is incidental 
(5%). The 36% of the parents experienced discrimination in the field of health 
care. The care of people with disabilities lacks from the health visitors’ graduate 
training that makes early recognition and the care more difficult. 
CONCLUSIONS: There is no comprehensive strategy in Hungary for the solution 
of the problems of the families raising autistic children. Developing a filtering 
system is necessary which would decrease the time span between the 
recognition and the diagnose. Our other goal is to build a comprehensive training 
system to broaden the knowledge of the health professionals.  
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OBJECTIVES: To evaluate the impact on alcohol-dependent patients’ reported 
outcomes (PROs) from the as-needed use of nalmefene versus placebo in 
reduction of alcohol consumption. METHODS: Two 6-month randomized, 
double-blind, placebo-controlled, efficacy studies assessing nalmefene 18mg 
(base) were conducted in Europe (ESENSE 1 [NCT00811720]; ESENSE 2 
[NCT00812461]). All patients took part in a motivational intervention (BRENDA) to 
support behavioural change and adherence to treatment. The Short Form Health 
Survey (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Drinker Inventory of 
Consequences (DrInC-2R) questionnaires were administered at baseline, weeks 
12 and 24. Post-hoc analyses of the pooled subgroup of patients with a high 
drinking risk level (men:>60 g/day; women:>40 g/day) assessed change from 
baseline using mixed models repeated measures. RESULTS: At baseline, the 
sample comprised 641 patients: 322 in the placebo group, 319 in the nalmefene 
group. The SF-36 Mental Component Score (MCS) and the EQ-5D health state 
score were 40.9±12.6 and 67.9±17.2 in the placebo group; 40.9±11.9 and 68.9±17.7 
in the nalmefene group. The MCS improvement at week 24 was significantly 
correlated to HDD (Heavy Drinking Day) and TAC (Total Alcohol Consumption) 
reduction and was significantly larger for the nalmefene group compared to 
placebo (p=0.0008): the means change from baseline were 5.74±0.79 and 2.65±0.78 
in the nalmefene and placebo groups respectively. For the EQ-5D, the mean 
change from baseline for nalmefene compared to placebo for the health state 
score and the utility index score was 3.46 (p=0.0124) and 0.03 points (p=0.0445) 
respectively. The mean DrInC-2R total score change from baseline to week 24 
was significantly correlated to HDD and TAC reduction. The improvement, 
indicating less alcohol-related problems, was significantly larger with nalmefene 
(17.86±1.31) than for placebo (14.64±1.30) (p=0.0292). CONCLUSIONS: As-needed 
use of nalmefene for reduction of alcohol consumption leads to statistically 
significantly larger improvements of alcohol dependent patients' PROs versus 
placebo.  
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OBJECTIVES: Complete qualitative concept elicitation (CE) and cognitive 
interviews leading to preliminary development of a patient-reported outcome 
(PRO) measure to assess treatment benefit in major depressive disorder (MDD) 
clinical trials. METHODS: Qualitative interviews were conducted with adult MDD 
patients in the US who recently experienced a major depressive event. All 
participants had a Hamilton Depression Rating Scale (HAM-D) total score >18 at 
screening. Experienced interviewers conducted CE and cognitive interview 
sessions using semi-structured interview guides. The CE interview guide was 
used to elicit spontaneous reports of symptom experiences along with probing to 
further explore and confirm concepts. The cognitive interview guide was 
developed to evaluate concept relevance, understandability, and structure of the 
draft items, and to facilitate further instrument refinement. All interview 
sessions were audio recorded and transcribed. The CE interviews were coded for 
qualitative content analysis using Atlas.ti, and the cognitive interview 
transcripts were summarized in cognitive report tables. RESULTS: Forty patients 
[mean age: 46.2; 67.5% female; 45.0% white (non-Hispanic)] participated in the CE 
interviews. Mean (SD) HAM-D total score of the participants was 24.4 (4.3). A total 
of 3,022 symptom codes, representing 91 different concepts were derived from 
the transcripts. Data from the CE interviews was considered alongside existing 
literature and clinical expert opinion during an item-generation meeting, leading 
to development of a 36-item measure with a 5-point response scale. 
Subsequently, fifteen patients participated in three waves of cognitive 
interviews, during which, one item was removed and four others were modified. 
CONCLUSIONS: The S-MDD is a 35-item PRO measure intended for use as an 
endpoint in MDD clinical trials to support medical product labeling. It was 
developed in accordance with the FDAs PRO Guidance and best practices. 
Qualitative interviews have provided evidence for content validity. Future 
quantitative studies will confirm the S-MDD’s measurement properties and 
support FDA qualification.  
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Citalopram (Celexa®) is in the selective serotonin reuptake inhibitor (SSRI) class 
of antidepressants. It is taken orally. Citalopram has been linked to both QT 
prolongation and Torsade de pointes (TdP), and these risks may be dose related. 
OBJECTIVES: To analyze the association between QT prolongation and TdP 
adverse events and the utilization of citalopram and other SSRIs. METHODS: 
This retrospective, descriptive study used the U.S. FDA Adverse Event Reporting 
System (FAERS) database. The database included 7,840,225 adverse events 
associated with SSRI drugs from 1997 fourth quarter to 2011 third quarter. The 
number of reported QT-prolongation and TdP cases associated with each study 
drug was calculated over time. Furthermore, for each case, dosage of the drug, 
when available in the report, was noted. RESULTS: A total of 1192 reported cases 
of QT prolongation and TdP were associated with SSRI drugs over the 14-year 
study period. Only 18% (219) of the adverse event reports were related 
specifically to citalopram, while the rest were related to other SSRI drugs. There 
were 911 reports for women, 252 for men, and 29 reports without gender 
information. The rate of QT prolongation and TdP associated with dosages of 20 
mg, 40 mg, and 60 mg of citalopram per day were 39%, 21%, and 2%, respectively. 
However, the percentage of reports without dosage information was 37%, so we 
were unable to draw any conclusions regarding dosage-related events. 
CONCLUSIONS: The results confirmed an association between the use of 
citalopram with QT prolongation and TdP. Furthermore, the association was not 
limited to citalopram alone but was widespread across the SSRIs. There were 
more adverse events observed for women than for men. Dose dependency was 
not established in this study. Future studies are warranted.  
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OBJECTIVES: To show how translatability assessment during the patient-
reported outcome (PRO) measure development process can be used to identify 
areas where wording changes are needed to improve and refine the measure. 
METHODS: A translatability assessment was conducted on a new 35-item PRO 
measure called Symptoms of Major Depressive Disorder (S-MDD) for evaluating 
treatment benefits in MDD. Five different languages were selected (French, 
Spanish, German, Chinese, and Russian). Each PRO item was reviewed and 
assigned a difficulty rating between 1 (no difficulty) and 5 (extreme difficulty) by 
an experienced translation consultant in each language. The difficult concepts 
for translation were compared to the problematic items for patient 
comprehension (from cognitive interviews) to identify difficult items for both 
translation and patient comprehension. RESULTS: Three items of the 35-item S-
MDD showed difficulty in patient comprehension and in the ability to accurately 
translate the concept. Due to the convergence of these two problematic findings 
during the PRO development, the item “how difficult was it for you to keep your 
mind free of worrying thoughts?” was changed to “how difficult was it for you to 
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stop thinking about your problems?” The item “how much have you looked 
forward to things with enjoyment?” was changed to “how much of the time did 
you feel enjoyment?”, and “how much have you felt useful?” was revised to read 
“how much of the time did you feel useful?” CONCLUSIONS: When 
translatability assessment is conducted prior to the finalization of a new 
measure, language changes can be implemented that will facilitate translation 
and cross cultural adaptation. When difficulties are encountered that may not 
warrant changes on their own, results from translatability assessments can also 
be useful in adding awareness and greater weight to other aspects of item 
structure that might need to be altered to improve the integrity and quality of 
the measure.  
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OBJECTIVES: Patients with schizophrenia frequently switch between 
antipsychotics, underscoring the need to ensure that important treatment 
outcomes such as health-related quality of life (HRQL) are achieved and 
maintained following the switch. This analysis evaluated changes in overall 
health-related quality of life among patients with schizophrenia switched from 
current antipsychotic treatment to lurasidone. METHODS: Stable, but 
symptomatic outpatients with schizophrenia were switched from their current 
antipsychotic to lurasidone, in a 6-week, open-label trial, conducted in the US. 
The Personal Evaluation of Transitions in Treatment (PETiT) is a validated 30-
item instrument measuring self-reported overall quality of life outcomes among 
patients with schizophrenia. In addition, PETiT assesses two domain scores on 
psychosocial functioning and adherence related attitude. Higher scores on PETiT 
denote better HRQL. PETiT scale was administered at baseline and study 
endpoint. Changes from baseline to study endpoint in PETiT total score (overall 
HRQL) and domain scores (psychosocial functioning and adherence) were 
compared using ANCOVA with baseline score, treatment, and pooled site as 
covariates. RESULTS: Of the 244 patients switched to lurasidone from other 
antipsychotics, patients with available data on PETiT (n=213) were included in 
the analysis. Mean PETiT total scores at baseline was 35.3 and at study endpoint 
was 38.5. Mean change from baseline to the study endpoint in the PETiT total 
score was 3.2, change in psychosocial functioning domain score was 2.5, and 
change in adherence domain score was 0.7, significant in all patient groups 
(p<0.001). CONCLUSIONS: The findings from this study indicate that patients 
switching from other antipsychotics to lurasidone experienced statistically 
significant improvement in HRQL, psychosocial functioning and adherence 
related attitude within six weeks of treatment. Further investigation regarding 
the effects of longer-term lurasidone treatment on HRQL outcomes is warranted.  
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OBJECTIVES: Caregiver burden and social support play a crucial role in 
moderating the treatment outcomes of children with autism. It is important for 
health care services researchers to consider the impact of these constructs while 
understanding treatment outcomes. The goal of this study is to provide a 
comprehensive review of instruments that have been used to measure caregiver 
burden and social support in autism. METHODS: A systematic literature review 
was conducted from January 2002 - December 2012 using the databases: Medline, 
PsychINFO, Cochrane, Mental measurements year book and Health and 
psychosocial instruments to identify instruments. The psychometric properties 
of the instruments have been assessed. Inclusion / exclusion criteria that were 
applied to the study are: language, availability of full text articles, and relevance 
to the topic of study. RESULTS: The review also yielded 20 instruments for 
measuring social support. Of these, 19 were generic and 1 was condition-specific. 
The most common domains included in the instruments were: instrumental 
support and emotional support. Some instruments consisted of domains based 
on source of social support such as informal support from friends, family and 
spouse. A review of the psychometric properties of these instruments indicated 
good reliability (Cronbach’s alpha 0.7 – 0.95). Caregiver burden has been studied 
less frequently as compared to social support. Caregiver burden was mostly 
measured using 4 instruments. Of these four instruments, Caregiver Strain 
Questionnaire has been validated in a population of parents of autistic children. 
It has good reliability (Cronbach’s alpha 0.75 – 0.93) CONCLUSIONS: Caregiver 
burden and social support are two important constructs that affect the quality of 
life (QoL) of caregivers of children with autistic disorder. Consideration of the 
nature and extent of caregiver burden and social support will also facilitate the 
development of appropriate interventions that can help improve caregivers’ 
quality of life (QoL) and functioning.  
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OBJECTIVES: This study investigates impairments and propensities for risky 
behaviors among adults diagnosed with attention-deficit/hyperactivity disorder 
(ADHD) in Europe (E) and the United States (US). METHODS: Data are from a web-
based survey of adults who self-report having an ADHD diagnosis. Data were 
gathered October-December 2012 in Germany, UK, Netherlands, Sweden and the 
U.S. Participants were asked questions regarding social, family, educational and 
work-related impairments and risky personal behaviors previously shown to be 
common among adults with ADHD. Chi-square tests of proportions were used to 
test for significant differences between European and U.S. participants reported 
below. RESULTS: Three hundred European and 100 US adults reporting a 
diagnosis of ADHD from a health care professional completed the survey online. 
60% of both European and US respondents agreed that ADHD has had a negative 
impact on their career success. Over one-in-four respondents reported a 
suspension some time during school (31% E vs. 23% US; p<0.05). Twenty-six 
percent of European respondents reported 3 or more traffic tickets within the 
past year (vs. 9% US; p<.05); 11% reported 3 or more automobile accidents during 
the same period (vs. 9% US). Eighteen percent of Europeans also reported having 
had more than three job-related accidents or injuries requiring medical attention 
during this period (vs. 2 % US; p<0.05). Over 40% of study participants reported 
illegal drug use at some time in the past (44% E vs. 48% US), with around 10% 
reporting citations for driving under the influence of alcohol or drugs (15% E vs. 9 
% US) or serving time in prison (11% each). Concern about exposure to a sexually 
transmitted disease was reported by 34% European and 44% US (p<0.05) study 
participants. CONCLUSIONS: ADHD Adults from Europe and the US report 
various impairments and risky behaviors possibly related to their condition, 
some more frequent among European than US participants.  
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OBJECTIVES: The impact of MDD on HRQOL is well documented, but little 
information exists about commonly used HRQoL instruments’ adherence to EMA 
requirements for psychometric properties and content relevance. This work 
examines commonly used HRoQL instruments for their relevance to MDD, based 
on their content, concepts measured and psychometric properties, and use in 
published MDD studies. METHODS: A qualitative research paper provided a 
conceptual model for MDD (1). The SF-36 Health Survey (SF-36), Sheehan 
Disability Scale (SDS), Quality of Life Enjoyment and Satisfaction Questionnaire 
(Q-LES-Q), Health Status Questionnaire-12 (HSQ-12) and EuroQol (EQ-5D) were 
mapped to this conceptual model to examine their relevance to MDD. The 
measures’ reliability, validity, responsiveness to change in depression and use in 
MDD trials and labelling were examined through review of classic databases 
(including: PROQOLID, PROLABEL, MEDLINE, PSYCHINFO, FDA, EMA). Where no 
information on MDD was available, data for mood disorders were explored. 
RESULTS: The SF-36, SDS, Q-LES-Q and EQ-5D have been widely used in MDD, 
with SDS and Q-LES-Q results included as part of approved EMA labelling claims 
in mood disorder indications. These instruments are clinically well established 
and the combination covers HRQoL concepts relevant to the MDD population 
[emotional/social/physical (specifically bodily pain)]; Q-LES-Q and SF-36 are the 
most comprehensive HRQoL measures. All instruments met EMA psychometric 
requirements for validity, reliability and responsiveness to changes in depressive 
symptoms and in elderly populations for the HSQ-12. Furthermore, the 
instruments have been linguistically validated for use in many countries. 
CONCLUSIONS: These commonly used instruments are relevant to MDD and 
meet EMA criteria for reliability, validity and responsiveness. Thus, we conclude 
that these instruments are appropriate for use in clinical programmes to assess 
the impact of MDD treatment on HRQoL and overall functioning, particularly to 
support claims in Europe.  
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OBJECTIVES: To build a conceptual model describing disease experience in 
adolescent ADHD (aged 13–17) and impact of treatment, in order to inform the 
development of a measurement strategy to evaluate interventions. Conceptual 
models that summarize key concepts in describing disease experience are useful 
for developing strategies to measure meaningful treatment outcomes. 
Adolescents are increasingly participating in making decisions about their health 
care. Hence, it is important to evaluate outcomes that are meaningful to them. 
METHODS: In preparation for patient interviews, focused searches of databases, 
clinical and regulatory guidelines, ADHD specific tools and conference abstracts 
were conducted as part of the literature review to identify concepts to 
understand the experiences of adolescents with ADHD from various 
perspectives. In addition, concept elicitation interviews with 10 clinicians, 3 
teachers, 10 peers and 10 siblings of adolescents with ADHD were conducted 
using semi-structured guides. Results from this preliminary stage were analyzed 
systematically; transcripts from the peer and sibling interviews were analyzed 
using a pre-defined coding dictionary, to identify concepts for the model. 
RESULTS: Disease-defining concepts in ADHD included core ADHD symptoms, 
